insulin lispro sold brand name humalog among others modified type medical insulin used treat type type used injection skin within insulin onset effects typically occurs within minutes lasts often longeracting insulin like insulin nph also common side effects include low blood serious side effects may include low blood use pregnancy breastfeeding generally works human insulin increasing amount glucose tissues take decreasing amount glucose made insulin lispro first approved use united states manufactured form human insulin amino acid commonly prescribed medication united states million insulin lispro used treat people type diabetes type people well shortacting insulin routinely changed insulin lispro may benefit advantages like flexibility common side effects include skin irritation site injection hypoglycemia hypokalemia serious side effects include anaphylaxis hypersensitivity recombinant dna technology final lysine proline residues cterminal end bchain reversed modification alter receptor binding blocks formation insulin dimers hexamers allows larger amounts active monomeric insulin immediately available postprandial manufactured form human insulin amino acids lysine proline switched end b chain insulin switch amino acids mimics insulinlike growth factor also lysine k proline p order positions insulin lispro brand name humalog granted marketing authorization european union april approved use united states june insulin lispro brand name liprolog granted marketing authorization european union may august combination drugs combining insulin lispro forms insulin approved use united states december insulin lispro sanofi granted marketing authorization biosimilar european union july insulin lispro injection brand name admelog approved use united states december january committee medicinal products human use chmp european union recommended granting marketing authorization insulin lispro acid brand name lyumjev treatment diabetes mellitus insulin lispro lyumjev approved use european union march united states june reported united states price vial humalog increased per april eli lilly company announced would produce version selling per chief executive said contribution fix problem high outofpocket costs americans living chronic conditions patients affordable drugs said public relations move countries pay vial march lilly announced program capping insulin prices per httpsenwikipediaorgwikiinsulinlispro